Tags

Type your tag names separated by a space and hit enter

Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Basic Clin Pharmacol Toxicol. 2007 Jun; 100(6):387-91.BC

Abstract

The prognostic significance of supplementing co-enzyme Q(10) (CoQ(10)), riboflavin and niacin (CoRN) along with tamoxifen to breast cancer patients was evaluated by measuring the serum cytokine levels of interleukin (IL)-1beta, IL-6, IL-8, tumour necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor. In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg, one dosage per day along with tamoxifen 10 mg twice a day. Serum cytokine levels were elevated in untreated breast cancer patients (Group II) and significantly reduced after tamoxifen therapy for more than 1 year (Group III). When group III breast cancer patients were supplemented with CoRN for 45 days (Group IV) and 90 days (Group V) along with tamoxifen, a significant reduction in cytokine levels were observed (P < 0.05). Such a decrease in serum cytokine levels after CoRN supplementation in breast cancer patients may suggest good prognosis and efficacy of the treatment, and might even offer protection from metastases and recurrence of cancer.

Authors+Show Affiliations

Department of Medical Biochemistry, Dr ALMP-GIBMS, University of Madras, Taramani Campus, Tamilnadu, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17516992

Citation

Premkumar, Vummidi Giridhar, et al. "Serum Cytokine Levels of Interleukin-1beta, -6, -8, Tumour Necrosis Factor-alpha and Vascular Endothelial Growth Factor in Breast Cancer Patients Treated With Tamoxifen and Supplemented With Co-enzyme Q(10), Riboflavin and Niacin." Basic & Clinical Pharmacology & Toxicology, vol. 100, no. 6, 2007, pp. 387-91.
Premkumar VG, Yuvaraj S, Vijayasarathy K, et al. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin Pharmacol Toxicol. 2007;100(6):387-91.
Premkumar, V. G., Yuvaraj, S., Vijayasarathy, K., Gangadaran, S. G., & Sachdanandam, P. (2007). Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic & Clinical Pharmacology & Toxicology, 100(6), 387-91.
Premkumar VG, et al. Serum Cytokine Levels of Interleukin-1beta, -6, -8, Tumour Necrosis Factor-alpha and Vascular Endothelial Growth Factor in Breast Cancer Patients Treated With Tamoxifen and Supplemented With Co-enzyme Q(10), Riboflavin and Niacin. Basic Clin Pharmacol Toxicol. 2007;100(6):387-91. PubMed PMID: 17516992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. AU - Premkumar,Vummidi Giridhar, AU - Yuvaraj,Srinivasan, AU - Vijayasarathy,Kothandaraman, AU - Gangadaran,Sitthu Govindaswamy Dinakaran, AU - Sachdanandam,Panchanatham, PY - 2007/5/23/pubmed PY - 2007/9/8/medline PY - 2007/5/23/entrez SP - 387 EP - 91 JF - Basic & clinical pharmacology & toxicology JO - Basic Clin. Pharmacol. Toxicol. VL - 100 IS - 6 N2 - The prognostic significance of supplementing co-enzyme Q(10) (CoQ(10)), riboflavin and niacin (CoRN) along with tamoxifen to breast cancer patients was evaluated by measuring the serum cytokine levels of interleukin (IL)-1beta, IL-6, IL-8, tumour necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor. In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg, one dosage per day along with tamoxifen 10 mg twice a day. Serum cytokine levels were elevated in untreated breast cancer patients (Group II) and significantly reduced after tamoxifen therapy for more than 1 year (Group III). When group III breast cancer patients were supplemented with CoRN for 45 days (Group IV) and 90 days (Group V) along with tamoxifen, a significant reduction in cytokine levels were observed (P < 0.05). Such a decrease in serum cytokine levels after CoRN supplementation in breast cancer patients may suggest good prognosis and efficacy of the treatment, and might even offer protection from metastases and recurrence of cancer. SN - 1742-7835 UR - https://www.unboundmedicine.com/medline/citation/17516992/Serum_cytokine_levels_of_interleukin_1beta__6__8_tumour_necrosis_factor_alpha_and_vascular_endothelial_growth_factor_in_breast_cancer_patients_treated_with_tamoxifen_and_supplemented_with_co_enzyme_Q_10__riboflavin_and_niacin_ L2 - https://doi.org/10.1111/j.1742-7843.2007.00065.x DB - PRIME DP - Unbound Medicine ER -